This review describes the use of 2-[18F]-fluoro-2-deoxyglucose (FDG)-PET to localize recurrence of differentiated thyroid carcinoma. It focuses on patients with persistent disease and normal results from conventional imaging, on changes in therapeutic management because of FDG-PET results and on the role of TSH stimulated FDG-PET scanning, Finally, it focuses on the prognostic significance of FDG uptake in patients with differentiated thyroid carcinoma.
- Sophie Leboulleux
- Pamela R Schroeder
- Paul W Ladenson